Key result
Sevelamer fails to reduce microbial translocation or inflammation in HIV, despite lowering atherogenic lipids.
Answers are grounded in this paper and cite their sources.
UNLABELLED: Abnormal levels of inflammation are associated with cardiovascular disease and mortality in human immunodeficiency virus (HIV)-infected patients. Microbial translocation, which may cause inflammation, is decreased by sevelamer in patients undergoing hemodialysis. In this single-arm study, we evaluated the effects of 8 weeks of sevelamer therapy on 36 HIV-infected subjects who were not receiving antiretroviral therapy. Sevelamer did not significantly change markers of microbial translocation, inflammation, or T-cell activation. During sevelamer treatment, however, levels of soluble tissue factor, low-density lipoprotein (LDL) cholesterol, and oxidized LDL cholesterol decreased significantly, whereas D-dimer levels increased. Thus, in this study population, sevelamer did not reduce microbial translocation but may have yielded cardiovascular benefits. CLINICAL TRIALS REGISTRATION: NCT 01543958.
No takes yet. Share an insight, caveat, or question.
Sandler et al. (2014) studied Untreated HIV infection (n=36). Sevelamer was evaluated on Markers of microbial translocation (lipopolysaccharide, soluble CD14), inflammation, and T-cell activation. Sevelamer for 8 weeks in 36 untreated HIV-infected subjects did not alter microbial translocation or inflammation, but significantly decreased soluble tissue factor, LDL, and oxidized LDL cholesterol.
Synapse has enriched 10 related papers. Consider them for comparative context: